ImmunityBio
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
- Conditions
- ChordomaUnresectable Malignant Neoplasm
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03647423
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.080: NANT Pancreatic Cancer Vaccine
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionBiological: bevacizumabBiological: AvelumabProcedure: SBRT
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03586869
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03574649
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.088: NANT Pancreatic Cancer Vaccine
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563144
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- Conditions
- mCRCColorectal Cancer Metastatic
- Interventions
- Procedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
- Conditions
- Hepatocellular Carcinoma RecurrentHepatocellular Carcinoma Non-resectable
- Interventions
- Biological: ETBX-011Biological: GI-4000Biological: haNK for infusionBiological: avelumabProcedure: SBRTBiological: Aldoxorubicin hydrochlorideBiological: ETBX-051Biological: ETBX-061Biological: GI-6207Biological: GI-6301Biological: N-803
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563170
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03554109
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 1538
- Registration Number
- NCT03520686
- Locations
- 🇺🇸
Alaska Urological Institute - Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: N-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for InfusionBiological: avelumabBiological: bevacizumabProcedure: SBRT
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03387085
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionProcedure: SBRTBiological: N-803
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387111
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States